This site is intended for health professionals only
Saturday 23 June 2018
Share |

Assay identifies lethal Clostridium difficile pathogen

Related articles

The time needed to genetically sequence the bacteria causing tuberculosis (Mtb) from patient samples has been reduced from weeks to days using a new technique developed by a UCL-led team
New mechanisms for a more personalised treatment – one drug for one bug
Accepta announce the launch of a pioneering fogging system, Accepta 8115 disinfectant, ideal for infection control and room disinfection purposes
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), has announced that it obtained CE Marking of the BD MAX™ Cdiff Assay. The assay detects the toxin B gene (tcdB), which has been shown to be present in all toxigenic C. difficile and is essential for disease.
Run on the fully automated BD MAX™ System, the assay is designed to rapidly and accurately identify patients with Clostridium difficile infection (CDI), including those caused by hypervirulent strains.

Ads by Google